CRL

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -3.81
Percentage change -1.96	%

Peers: IQV LDOS MEDP CVS PFE ILMN BMY LH MRK

| Held by: VTI VOO VB RSP VBK SPY IVV XLV IBB IWR

Scroll to Statements

Index	S&P 500	P/E	23.52	EPS (ttm)	8.10	Insider Own	1.08%	Shs Outstand	51.13M	Perf Week	-0.70%
Market Cap	9.55B	Forward P/E	18.46	EPS next Y	10.32	Insider Trans	-5.86%	Shs Float	50.59M	Perf Month	-7.79%
Income	418.71M	PEG	5.80	EPS next Q	2.54	Inst Own	103.05%	Short Float	4.31%	Perf Quarter	-6.51%
Sales	4.06B	P/S	2.35	EPS this Y	-4.42%	Inst Trans	-0.68%	Short Ratio	3.13	Perf Half Y	-9.08%
Book/sh	73.97	P/B	2.57	EPS next Y	1.16%	ROA	5.36%	Short Interest	2.18M	Perf Year	-12.63%
Cash/sh	4.20	P/C	45.36	EPS next 5Y	4.06%	ROE	11.81%	52W Range	176.48 - 275.00	Perf YTD	-19.43%
Dividend Est.	-	P/FCF	17.04	EPS past 5Y	14.84%	ROI	6.40%	52W High	-30.74%	Beta	1.38
Dividend TTM	-	Quick Ratio	1.14	Sales past 5Y	12.89%	Gross Margin	32.70%	52W Low	7.92%	ATR (14)	6.61
Dividend Ex-Date	-	Current Ratio	1.48	EPS Y/Y TTM	-12.39%	Oper. Margin	15.05%	RSI (14)	44.54	Volatility	3.44% 3.17%
Employees	21800	Debt/Eq	0.73	Sales Y/Y TTM	-3.67%	Profit Margin	10.31%	Recom	2.70	Target Price	211.25
Option/Short	Yes / Yes	LT Debt/Eq	0.73	EPS Q/Q	-21.38%	Payout	0.00%	Rel Volume	0.79	Prev Close	194.27
Sales Surprise	3.46%	EPS Surprise	6.91%	Sales Q/Q	-1.64%	Earnings	Nov 06 BMO	Avg Volume	695.98K	Price	190.46
SMA20	-2.26%	SMA50	-1.91%	SMA200	-11.76%	Trades		Volume	546,452	Change	-1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Downgrade	CLSA	Hold → Underperform	$164
Nov-07-24	Upgrade	CLSA	Underperform → Hold	$205
Oct-23-24	Initiated	CLSA	Underperform	$167
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line	$225 → $190
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$250 → $215
Oct-01-24	Downgrade	Citigroup	Neutral → Sell	$215 → $175
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral	$239 → $191
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral	$270 → $205
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral	$235
Jun-06-24	Initiated	Goldman	Buy	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform	$212
Jul-10-23	Downgrade	Citigroup	Buy → Neutral	$260 → $225
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy	$255
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy	$240
Aug-25-22	Initiated	Credit Suisse	Outperform	$285
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$350 → $250

Show Previous Ratings

Dec-06-24 11:31AM	Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report? (Zacks)
Dec-05-24 08:00AM	Charles River Introduces Global Biotech Incubator Program (Business Wire)
Dec-02-24 08:00AM	Charles River Laboratories to Present at Evercore ISI Investor Conference (Business Wire)
Nov-11-24 09:15AM	Charles River (CRL) International Revenue in Focus: Trends and Expectations (Zacks)
08:00AM	Charles River Laboratories to Present at UBS and Jefferies Conferences (Business Wire)
04:20AM	Loading…
Nov-07-24 04:20AM	Q3 2024 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)
02:19AM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
02:14AM	Charles River Laboratories International Inc (CRL) Q3 2024 Earnings Call Highlights: Navigating ... (GuruFocus.com)
12:02AM	Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight (GuruFocus.com)
Nov-06-24 09:30AM	Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) +13.53%
08:10AM	Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:08AM	Charles River: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces Third-Quarter 2024 Results (Business Wire)
Nov-04-24 09:16AM	Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Oct-30-24 10:01AM	Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
12:10PM	Loading…
Oct-29-24 12:10PM	Why Charles River (CRL) is Poised to Beat Earnings Estimates Again (Zacks)
Oct-21-24 07:45AM	FibroBiologics and Charles River link for chronic disease therapies manufacture (Pharmaceutical Technology)
Oct-17-24 08:00AM	Charles River Launches New Retrogenix Non-Human Protein Library (Business Wire)
Oct-16-24 04:30PM	Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call (Business Wire)
Oct-03-24 08:00AM	Charles River Provides Translational Expertise at Neuroscience 2024 (Business Wire)
Oct-02-24 08:00AM	Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease (Business Wire)
Sep-17-24 08:00AM	Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research (Business Wire)
Sep-06-24 11:31AM	Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report? (Zacks)
10:05AM	Higher Interest Environment Negatively Impacted Charles River Laboratories (CRL) (Insider Monkey)
Sep-04-24 09:21AM	Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience (PR Newswire)
Sep-03-24 04:30PM	Charles River Laboratories to Present at Baird and Morgan Stanley Conferences (Business Wire)
Aug-28-24 04:46AM	Charles River Laboratories International (CRL) Fell Due to a More Cautious Funding Environment (Insider Monkey)
Aug-19-24 06:53AM	Terumo and Charles River demonstrate effectiveness of CGT manufacturing device (Medical Device Network)
Aug-12-24 07:01PM	Insider Sale: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL) (GuruFocus.com)
09:15AM	Why Charles River (CRL) International Revenue Trends Deserve Your Attention (Zacks)
01:49PM	Loading…
Aug-09-24 01:49PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
Aug-08-24 06:30AM	Big Pharma Cuts R&D, Sending Shudders Through Industry (The Wall Street Journal)
01:04AM	Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight (GuruFocus.com)
01:03AM	Q2 2024 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 08:35PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) -12.60%
05:36PM	S&P 500 Gains and Losses Today: Fortinet Stock Surges on Earnings Beat (Investopedia)
04:15PM	Charles River Labs Plummets 14% On 'Bleaker' Expectations For 2024 (Investor's Business Daily)
01:30PM	Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down (Zacks)
01:06PM	Charles River Labs Says It Expects Sales To Fall, Sending Its Stock Tumbling (Investopedia)
09:30AM	Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings (Zacks)
08:10AM	Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
07:07AM	Charles River: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces Second-Quarter 2024 Results (Business Wire)
Aug-05-24 09:16AM	Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jul-30-24 07:28PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
08:00AM	Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development (Business Wire)
Jul-24-24 08:43AM	Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings (Zacks)
08:00AM	Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery (Business Wire)
Jul-16-24 04:30PM	Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call (Business Wire) +5.11%
Jul-09-24 09:38AM	Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy (Zacks)
Jul-08-24 08:00AM	Charles River to Perform Plasmid Manufacturing for AAVantgarde (Business Wire)
Jul-05-24 09:23AM	Charles River (CRL) Could be an Apt Pick Right Now: Here's Why (Zacks)
Jun-27-24 10:23AM	Charles River's (CRL) RMS Growth Aids Amid FX Headwind (Zacks)
Jun-26-24 07:46AM	Charles River (CRL) Inks CDMO Deal With Gates Institutes (Zacks)
Jun-25-24 08:00AM	Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus (Business Wire)
Jun-18-24 08:49AM	The CRO Sector Looks Appealing, Says Goldman Sachs Here Are 2 Stocks to Consider (TipRanks)
07:53AM	Charles River (CRL) Advances in T-Cell Therapy With New Alliance (Zacks)
04:52AM	Charles River and Captain T Cell sign vector production agreement (Pharmaceutical Technology)
Jun-17-24 08:00AM	Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy (Business Wire)
Jun-11-24 08:13AM	Charles River (CRL) Partners to Reduce Animal Research Usage (Zacks)
08:00AM	Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives (Business Wire)
Jun-06-24 08:00AM	Charles River Laboratories Expands Access to CRADL Contract Vivarium Space in Somerville (Business Wire)
Jun-04-24 08:00AM	Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research (Business Wire)
Jun-03-24 08:00AM	Charles River Laboratories to Present at William Blair and Jefferies Conferences (Business Wire)
May-31-24 10:42AM	Charles River (CRL) Launches Viral Vector Tech Transfer Program (Zacks)
May-30-24 08:00AM	Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development (Business Wire)
07:17AM	Reasons to Hold Charles River (CRL) in Your Portfolio Now (Zacks)
May-24-24 11:38AM	Charles River (CRL) Banks on RMS Growth Amid Competition (Zacks)
May-16-24 08:06PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
May-14-24 07:02PM	Insider Sale: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL) (GuruFocus.com)
May-13-24 12:15PM	Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock (Zacks)
09:40AM	Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term (Zacks)
06:55AM	TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260 (MT Newswires)
May-10-24 04:06PM	Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:06AM	JPMorgan Adjusts Price Target on Charles River Laboratories International to $270 From $280 (MT Newswires)
07:22AM	Jefferies Adjusts Price Target on Charles River Laboratories International to $226 From $235 (MT Newswires)
06:14AM	Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300 (MT Newswires)
06:08AM	Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282 (MT Newswires)
01:03AM	Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight (GuruFocus.com)
May-09-24 11:22PM	Q1 2024 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)
06:13PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
12:22PM	Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y (Zacks)
11:57AM	CRL Stock Earnings: Charles River Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:18AM	Charles River beats first-quarter estimates, reaffirms annual forecast (Reuters)
07:49AM	Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance (MT Newswires)
07:34AM	Charles River Laboratories Reaffirms FY24 Outlook; Q1 Results Top Estimates (RTT News)
07:12AM	Charles River: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces First-Quarter 2024 Results (Business Wire)
May-08-24 03:29PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
06:00AM	The 7 Best Growth Stocks to Buy in May 2024 (InvestorPlace)
May-06-24 09:15AM	Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
May-02-24 08:00AM	Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP (Business Wire)
Apr-24-24 12:47PM	Charles River (CRL) to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-22-24 08:00AM	Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally (Business Wire)
Apr-18-24 12:09PM	Notice to Long-Term Charles River Laboratories International, Inc. (CRL) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
Apr-16-24 11:50AM	Here's Why You Should Retain Charles River (CRL) Stock Now (Zacks)
08:00AM	Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing (Business Wire)
Apr-12-24 08:00AM	Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call (Business Wire)
Apr-11-24 09:10AM	Charles River (CRL) Forges Collaboration With Ship of Theseus (Zacks)

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WALLMAN RICHARD F	Director	Nov 07 '24	Sale	216.12	6,621	1,430,918	12,386	Nov 12 04:38 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Sale	216.50	1,000	216,500	0	Nov 12 04:38 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Proposed Sale	216.01	12,161	2,626,923		Nov 07 04:23 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 08 '24	Sale	199.36	1,780	354,861	22,521	Aug 12 04:13 PM
Joseph LaPlume	Officer	Aug 08 '24	Proposed Sale	196.63	1,780	350,000		Aug 08 01:34 PM
FOSTER JAMES C	Chairman, President and CEO	Aug 01 '24	Sale	250.00	25,000	6,250,000	188,251	Aug 05 04:04 PM
FOSTER JAMES C	Officer	Aug 01 '24	Proposed Sale	250.00	25,000	6,250,000		Aug 01 04:07 PM
MASSARO GEORGE	Director	May 15 '24	Sale	235.62	332	78,225	5,855	May 16 04:35 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	May 10 '24	Sale	226.97	1,304	295,969	23,276	May 14 04:49 PM
Knell Michael Gunnar	CSVP&Chief Accounting Officer	Mar 08 '24	Sale	267.52	808	216,156	7,024	Mar 11 04:42 PM
Knell Michael Gunnar	CSVP&Chief Accounting Officer	Mar 04 '24	Sale	261.05	2,750	717,890	7,832	Mar 05 04:54 PM
Parisotto Shannon M	CEVP, Disc & Safety Assessment	Feb 29 '24	Sale	253.45	3,786	959,545	4,792	Mar 04 04:09 PM
Creamer Victoria L	EVP & Chief People Officer	Feb 29 '24	Sale	253.70	5,000	1,268,500	13,550	Mar 01 05:37 PM
Barbo William D	Corporate Executive VP & CCO	Feb 22 '24	Sale	248.50	4,050	1,006,425	22,879	Feb 23 04:57 PM
Parisotto Shannon M	CEVP, Disc & Safety Assessment	Feb 15 '24	Option Exercise	144.67	5,882	850,949	8,478	Feb 20 05:32 PM
Parisotto Shannon M	CEVP, Disc & Safety Assessment	Feb 15 '24	Sale	241.20	5,882	1,418,767	2,596	Feb 20 05:32 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Feb 15 '24	Sale	238.93	838	200,223	24,620	Feb 20 05:20 PM
FOSTER JAMES C	Chairman, President and CEO	Jan 29 '24	Option Exercise	144.67	17,436	2,522,466	227,827	Jan 31 04:59 PM
Girshick Birgit	Corporate Executive VP & COO	Jan 10 '24	Option Exercise	215.19	5,916	1,273,064	50,365	Jan 11 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Charles River Laboratories International Inc

Upgrade your FINVIZ experience